Safety and reactogenicity of the BNT162b2 COVID-19 vaccine: Development, post-marketing surveillance, and real-world data

References

• Kassianos G, Puig-Barbera J, Dinse H, Teufel M, Tureci O, Pather S. Addressing COVID-19 vaccine hesitancy. Drugs Context. 2022;11: doi:10.7573/dic.2021-12-3.
   PubMedGoogle Scholar
• Kalinke U, Barouch DH, Rizzi R, Lagkadinou E, Tureci O, Pather S, Neels P. Clinical development and approval of COVID-19 vaccines. Expert Rev Vaccines. 2022;21(5):609–16. doi:10.1080/14760584.2022.2042257.
   PubMed Web of Science ®Google Scholar
• Marinus R, Mofid S, Mpandzou M, Kühler TC. Rolling Reviews During COVID-19: The European Union Experience in a Global Context. Clin Ther. 2022;44:352–63. doi:10.1016/j.clinthera.2022.01.001.
   PubMed Web of Science ®Google Scholar
• Vaccine Research and Development. [Internet]. Johns Hopkins University & Medicine; 2023 [accessed 2023 Mar 3]. https://coronavirus.jhu.edu/vaccines/timeline.
   Google Scholar
• Emergency use authorization for vaccines to prevent COVID-19: guidance for industry. [Internet]. US Food And Drug Administration; 2022 [accessed 2022 Jul 12]. https://www.fda.gov/media/142749/download.
   Google Scholar
• Pfizer and BioNTech submit a variation to EMA with the data in support of a booster dose of COMIRNATY®. [Internet]. Pfizer; 2021 [accessed 2023 May 1]. https://www.pfizer.com/news/announcements/pfizer-and-biontech-submit-variation-ema-data-support-booster-dose-comirnatyr.
   Google Scholar
• Cole A, Webster P, Van Liew D, Salas M, Aimer O, Malikova MA. Safety surveillance and challenges in accelerated COVID-19 vaccine development. Ther Adv Drug Saf. 2022;13:20420986221116452. doi:10.1177/20420986221116452.
   Web of Science ®Google Scholar
• EMA considerations on COVID-19 vaccine approval. [Internet]. European Medicines Agency; 2020 [accessed 2023 Feb 27]. https://www.ema.europa.eu/en/documents/other/ema-considerations-covid-19-vaccine-approval_en.pdf.
   Google Scholar
• Reflection paper on the regulatory requirements for vaccines intended to provide protection against variant strain(s) of SARS-CoV-2. [Internet]. European Medicines Agency; 2021 [accessed 2021 February 23]. https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-regulatory-requirements-vaccines-intended-provide-protection-against-variant_en.pdf.
   Google Scholar
• COVID-19 vaccines: development, evaluation, approval and monitoring. [Internet]. European Medicines Agency; 2021 [accessed 2021 Jun 18]. https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-development-evaluation-approval-monitoring.
   Google Scholar
• Durand J, Dogne JM, Cohet C, Browne K, Gordillo-Maranon M, Piccolo L, Zaccaria C, Genov G. Safety monitoring of COVID-19 vaccines: perspective from the European Medicines Agency. Clin Pharmacol Ther. 2023;113:1223–34. doi:10.1002/cpt.2828.
   PubMed Web of Science ®Google Scholar
• Comirnaty. [Internet]. European Medicines Agency; 2023 [accessed 2023 Feb 23]. https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty.
   Google Scholar
• Younus MM, Al-Jumaili AA. An overview of COVID-19 vaccine safety and post-marketing surveillance systems. Innov Pharm. 2021;12:10. doi:10.24926/iip.v12i4.4294.
   Google Scholar
• Jung HN, Lee SY, Lee S, Youn H, Im HJ. Lipid nanoparticles for delivery of RNA therapeutics: current status and the role of in vivo imaging. Theranostics. 2022;12:7509–31. doi:10.7150/thno.77259.
   PubMed Web of Science ®Google Scholar
• Pascolo S. Vaccines against COVID-19: priority to mRNA-based formulations. Cells. 2021;10:2716. doi:10.3390/cells10102716.
   PubMed Web of Science ®Google Scholar
• Global regulatory workshop on COVID-19 vaccine development. [Internet]. International coalition of medicines regulatory authorities; 2020 [accessed 2023 May 23]. https://www.icmra.info/drupal/news/March2020/summary.
   Google Scholar
• Rohde CM, Lindemann C, Giovanelli M, Sellers RS, Diekmann J, Choudhary S, Ramaiah L, Vogel AB, Chervona Y, Muik A. et al. Toxicological assessments of a pandemic COVID-19 vaccine—demonstrating the suitability of a platform approach for mRNA vaccines. Vaccines (Basel). 2023;11(2):417. doi:10.3390/vaccines11020417.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603–15. doi:10.1056/NEJMoa2034577.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C. et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603–15. doi:10.1056/NEJMoa2034577.
   PubMed Web of Science ®Google Scholar
• Investigator’s brochure, BNT162/PF-07302048. [Internet]. BioNtech; 2020 [accessed 2023 May 23]. https://www.tga.gov.au/sites/default/files/foi-2183-09.pdf.
   Google Scholar
• Comirnaty COVID-19 vaccine. Summary of product characteristics. [Internet]. European Medicines Agency; 2022 [accessed 2022 Sep 7]. https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_en.pdf.
   Google Scholar
• Bowman CJ, Bouressam M, Campion SN, Cappon GD, Catlin NR, Cutler MW, Diekmann J, Rohde CM, Sellers RS, Lindemann C. Lack of effects on female fertility and prenatal and postnatal offspring development in rats with BNT162b2, a mRNA-based COVID-19 vaccine. Reprod Toxicol. 2021;103:28–35. doi:10.1016/j.reprotox.2021.05.007.
   PubMed Web of Science ®Google Scholar
• Vogel AB, Kanevsky I, Che Y, Swanson KA, Muik A, Vormehr M, Kranz LM, Walzer KC, Hein S, Guler A. et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature. 2021;592:283–9. doi:10.1038/s41586-021-03275-y.
   PubMed Web of Science ®Google Scholar
• Mahanty S, Prigent A, Garraud O. Immunogenicity of infectious pathogens and vaccine antigens. BMC Immunol. 2015;16:31. doi:10.1186/s12865-015-0095-y.
   PubMed Web of Science ®Google Scholar
• Ashmawy R, Hamdy NA, Elhadi YAM, Alqutub ST, Esmail OF, Abdou MSM, Reyad OA, El-Ganainy SO, Gad BK, Nour El-Deen AE. et al. A meta-analysis on the safety and immunogenicity of covid-19 vaccines. J Prim Care Community Health. 2022;13:21501319221089255. doi:10.1177/21501319221089255.
   Web of Science ®Google Scholar
• A trial investigating the safety and effects of four BNT162 vaccines against COVID-2019 in healthy and immunocompromised adults (NCT04380701). [Internet]. Clinicaltrials.gov; 2023 [accessed 2023 Feb 22]. https://clinicaltrials.gov/ct2/show/NCT04380701.
   Google Scholar
• Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, Baum A, Pascal K, Quandt J, Maurus D. et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020;586:594–9. doi:10.1038/s41586-020-2814-7.
   PubMed Web of Science ®Google Scholar
• Sahin U, Muik A, Vogler I, Derhovanessian E, Kranz LM, Vormehr M, Quandt J, Bidmon N, Ulges A, Baum A. et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature. 2021;595:572–7. doi:10.1038/s41586-021-03653-6.
   PubMed Web of Science ®Google Scholar
• Walsh EE, Frenck RW Jr., Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R. et al. Safety and immunogenicity of two RNA-Based covid-19 vaccine candidates. N Engl J Med. 2020;383:2439–50. doi:10.1056/NEJMoa2027906.
   PubMed Web of Science ®Google Scholar
• Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Raabe V, Bailey R, Swanson KA. et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586:589–93. doi:10.1038/s41586-020-2639-4.
   PubMed Web of Science ®Google Scholar
• Haranaka M, Baber J, Ogama Y, Yamaji M, Aizawa M, Kogawara O, Scully I, Lagkadinou E, Tureci Ӧ, Sahin U. et al. A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults. Nat Commun. 2021;12:7105. doi:10.1038/s41467-021-27316-2.
   PubMed Web of Science ®Google Scholar
• Li J, Hui A, Zhang X, Yang Y, Tang R, Ye H, Ji R, Lin M, Zhu Z, Tureci O. et al. Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. Nat Med. 2021;27(6):1062–70. doi:10.1038/s41591-021-01330-9.
   PubMed Web of Science ®Google Scholar
• COMIRNATY Package Insert [Internet]. Food and Drug Administration (FDA). 2023 [accessed 2023 May 23]. https://www.fda.gov/media/151707/download.
   Google Scholar
• Thomas SJ, Moreira ED Jr., Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Perez Marc G, Polack FP, Zerbini C. et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine through 6 months. N Engl J Med. 2021;385:1761–73. doi:10.1056/NEJMoa2110345.
   PubMed Web of Science ®Google Scholar
• Hui AM, Li J, Zhu L, Tang R, Ye H, Lin M, Ge L, Wang X, Peng F, Wu Z. et al. Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: a phase 2 randomised clinical trial. Lancet Reg Health West Pac. 2022;29:100586. doi:10.1016/j.lanwpc.2022.100586.
   PubMedGoogle Scholar
• Walter EB, Talaat KR, Sabharwal C, Gurtman A, Lockhart S, Paulsen GC, Barnett ED, Munoz FM, Maldonado Y, Pahud BA. et al. Evaluation of the BNT162b2 COVID-19 vaccine in children 5 to 11 years of age. N Engl J Med. 2022;386:35–46. doi:10.1056/NEJMoa2116298.
   PubMed Web of Science ®Google Scholar
• Munoz FM, Sher LD, Sabharwal C, Gurtman A, Xu X, Kitchin N, Lockhart S, Riesenberg R, Sexter JM, Czajka H. et al. Evaluation of BNT162b2 COVID-19 vaccine in children younger than 5 years of age. N Engl J Med. 2023;388:621–34. doi:10.1056/NEJMoa2211031.
   PubMed Web of Science ®Google Scholar
• Frenck RW Jr., Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, Perez JL, Walter EB, Senders S, Bailey R. et al. Safety, immunogenicity, and efficacy of the BNT162b2 COVID-19 vaccine in adolescents. N Engl J Med. 2021;385(3):239–50. doi:10.1056/NEJMoa2107456.
   PubMed Web of Science ®Google Scholar
• Moreira ED Jr., Kitchin N, Xu X, Dychter SS, Lockhart S, Gurtman A, Perez JL, Zerbini C, Dever ME, Jennings TW. et al. Safety and efficacy of a third dose of BNT162b2 covid-19 vaccine. N Engl J Med. 2022;386:1910–21. doi:10.1056/NEJMoa2200674.
   PubMed Web of Science ®Google Scholar
• Winokur P, Gayed J, Fitz-Patrick D, Thomas SJ, Diya O, Lockhart S, Xu X, Zhang Y, Bangad V, Schwartz HI. et al. Bivalent omicron BA.1–adapted BNT162b2 booster in adults older than 55 years. N Engl J Med. 2023;388(3):214–27. doi:10.1056/NEJMoa2213082.
   PubMed Web of Science ®Google Scholar
• Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine. [Internet]. BioNtech; 2022 [accessed 2023 Mar 29]. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-updated-clinical-data-omicron.
   Google Scholar
• Gayed J, Diya O, Lowry FS, Xu X, Bangad V, Mensa F, Zou J, Xie X, Hu Y, Lu C. et al. Safety and immunogenicity of the monovalent omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine in individuals ≥12 years old: a phase 2/3 trial. Vaccines. 2024;12(2): 118. doi:10.3390/vaccines12020118.
   Google Scholar
• Pather S, Muik A, Rizzi R, Mensa F. Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early omicron era. Expert Rev Vaccines. 2023;22:650–61. doi:10.1080/14760584.2023.2232851.
   PubMed Web of Science ®Google Scholar
• Pfizer/BioNTech COVID-19 Omicron-Modified Vaccine Options. [Internet]. Pfizer; BioNtech; 2022 [accessed 2023 May 23]. https://www.fda.gov/media/159496/download.
   Google Scholar
• Zou J, Kurhade C, Patel S, Kitchin N, Tompkins K, Cutler M, Cooper D, Yang Q, Cai H, Muik A. et al. Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with bivalent vaccine. N Engl J Med. 2023;388(9):854–7. doi:10.1056/NEJMc2214916.
   PubMed Web of Science ®Google Scholar
• Statement on the antigen composition of COVID-19 vaccines. [Internet]. World Health Organization; 2023 [accessed 2023 May 24]. https://www.who.int/news/item/18-05-2023-statement-on-the-antigen-composition-of-covid-19-vaccines.
   Google Scholar
• ECDC-EMA statement on updating COVID-19 vaccines composition for new SARS-CoV-2 virus variants. [Internet]. European Centre For Disease Prevention And Control (ECDC) And European Medicines Agency (EMA); 2023 [ accessed 2023 22 August]. https://www.ema.europa.eu/en/documents/other/ecdc-ema-statement-updating-covid-19-vaccines-composition-new-sars-cov-2-virus-variants_en.pdf.
   Google Scholar
• Updated COVID-19 vaccines for use in the United States Beginning in Fall 2023. [Internet]. United States Food And Drug Administration; 2023 [accessed 2023 22 Aug]. https://www.fda.gov/vaccines-blood-biologics/updated-covid-19-vaccines-use-united-states-beginning-fall-2023.
   Google Scholar
• European Medicines Agency. Comirnaty: eMA recommends approval of adapted COVID-19 vaccine targeting omicron XBB.1.5. 2023.
   Google Scholar
• Medicines and Healthcare products Regulatory Agency. MHRA approves Pfizer/BioNTech’s adapted COVID-19 vaccine (comirnaty) that targets omicron XBB.1.5. 2023.
   Google Scholar
• Public summary of the risk management plan, comirnaty (COVID-19 mRNA vaccine). [Internet]. Pfizer; 2022 [accessed 2023 May 23]. https://www.swissmedic.ch/dam/swissmedic/de/dokumente/marktueberwachung/rmp/covid-19_mrna_vaccine_comirnaty-rmp-summary.pdf.download.pdf/Covid-19%20mRNA%20Vaccine_Comirnaty_riskmgtsystem-summaryrmpversion1.pdf.
   Google Scholar
• Prugger C, Spelsberg A, Keil U, Erviti J, Doshi P. Evaluating COVID-19 vaccine efficacy and safety in the post-authorisation phase. BMJ. 2021;375:e067570. doi:10.1136/bmj-2021-067570.
   PubMedGoogle Scholar
• FDA Approves First COVID-19 Vaccine. [Internet]. Food And Drug Administration; 2021 [accessed 2023 May 23]. https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine.
   Google Scholar
• Meeting highlights from the Pharmacovigilance risk assessment committee (PRAC) 29 November - 2 December 2021. [Internet]. European Medicines Agency; 2021 [accessed 2023 23 May]. https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-29-november-2-december-2021.
   Google Scholar
• Ischemic Stroke. COVID-19 and Influenza in Adults Ages ≥ 65 Years: Interpretation & Next Steps. [Internet]. Twentyman E; 2023 [accessed 2023 Feb 28]. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-02/slides-02-24/COVID-05-Twentyman-508.pdf.
   Google Scholar
• European Medicines Agency. Report on pharmacovigilance tasks from EU member states and the European medicines agency (EMA) 2019–2022. 2023.
   Google Scholar
• EudraVigilance. [Internet]. European Medicines Agency; 2023 [accessed 2023 Feb 28]. https://www.ema.europa.eu/en/human-regulatory/research-development/pharmacovigilance/eudravigilance.
   Google Scholar
• United States Food and Drug Administration. Letter Of Authorization (Reissued). 2023.
   Google Scholar
• Guideline on Good Pharmacovigilance practices (GVP). Module VI – collection, management and submission of reports of suspected adverse reactions to medicinal products (Rev 2). [Internet]. European Medicines Agency; 2017 [accessed 2023 May 23]. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-submission-reports_en.pdf.
   Google Scholar
• Chandler RE. Optimizing safety surveillance for COVID-19 vaccines. Nat Rev Immunol. 2020;20:451–2. doi:10.1038/s41577-020-0372-8.
   PubMed Web of Science ®Google Scholar
• Vaccine Safety Monitoring. [Internet]. United States Centers For Disease Control And Prevention; 2020 [accessed 2023 Feb 28]. https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/index.html.
   Google Scholar
• COVID-19 vaccine safety surveillance. [Internet]. United States food and drug administration; 2021 [accessed 2023 Feb 28]. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/covid-19-vaccine-safety-surveillance.
   Google Scholar
• VigiBase. WHO’s global database signalling harm and pointing to safer use. [Internet]. Uppsala Monitoring Centre; 2022 [accessed 2023 Feb 28]. https://who-umc.org/vigibase/vigibase-who-s-global-database/.
   Google Scholar
• COVID-19 vaccine tracker. [Internet]. European Centre for Disease Prevention and Control; 2023 [accessed 2023 Feb 28]. https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#distribution-tab.
   Google Scholar
• COVID-19 vaccinations in the United States. [Internet]. US Centers for Disease Control and Prevention; 2023 [accessed 2023 February 28]. https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-people-booster-percent-pop5.
   Google Scholar
• Petousis-Harris H. Assessing the safety of COVID-19 vaccines: a primer. Drug Saf. 2020;43:1205–10. doi:10.1007/s40264-020-01002-6.
   PubMed Web of Science ®Google Scholar
• COVID-19 vaccines: Safety surveillance manual second edition. [Internet]. World Health Organization; 2021 [accessed 2023 May 1]. https://apps.who.int/iris/bitstream/handle/10665/345178/9789240032781-eng.pdf;sequence=1.
   Google Scholar
• COVID-19 AESI including status of associated Brighton case definitions, updated (October 2022). [Internet]. Brighton Collaboration; 2022 [accessed 2023 May 23]. https://brightoncollaboration.us/wp-content/uploads/2022/11/Updated-COVID-19-AESI-list_Oct2022.pdf.
   Google Scholar
• Shemer A, Pras E, Hecht I. Peripheral facial nerve palsy following BNT162b2 (COVID-19) vaccination. Isr Med Assoc J. 2021;23:143–4.
   PubMed Web of Science ®Google Scholar
• Cirillo N. Reported orofacial adverse effects of COVID-19 vaccines: the knowns and the unknowns. J Oral Pathol Med. 2021;50:424–7. doi:10.1111/jop.13165.
   PubMed Web of Science ®Google Scholar
• Shemer A, Pras E, Einan-Lifshitz A, Dubinsky-Pertzov B, Hecht I. Association of COVID-19 vaccination and facial nerve palsy: a case-control study. JAMA Otolaryngol Head Neck Surg. 2021;147:739–43. doi:10.1001/jamaoto.2021.1259.
   PubMed Web of Science ®Google Scholar
• Bertin B, Grenet G, Pizzoglio-Billaudaz V, Lepelley M, Atzenhoffer M, Vial T. Vaccines and Bell’s palsy: a narrative review. Therapie. 2022;78:279–92. doi:10.1016/j.therap.2022.07.009.
   PubMed Web of Science ®Google Scholar
• Wan EYF, Chui CSL, Lai FTT, Chan EWY, Li X, Yan VKC, Gao L, Yu Q, Lam ICH, Chun RKC. et al. Bell’s palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study. Lancet Infect Dis. 2022;22:64–72. doi:10.1016/S1473-3099(21)00451-5.
   PubMed Web of Science ®Google Scholar
• Ahsanuddin S, Nasser W, Roy SC, Povolotskiy R, Paskhover B. Facial paralysis and vaccinations: a vaccine adverse event reporting system review. Fam Pract. 2022;39:80–4. doi:10.1093/fampra/cmab068.
   PubMed Web of Science ®Google Scholar
• Lewis DJ, Huo Z, Barnett S, Kromann I, Giemza R, Galiza E, Woodrow M, Thierry-Carstensen B, Andersen P, Novicki D. et al. Transient facial nerve paralysis (Bell’s palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One. 2009;4:e6999. doi:10.1371/journal.pone.0006999.
   PubMed Web of Science ®Google Scholar
• Gargano JW, Wallace M, Hadler SC, Langley G, Su JR, Oster ME, Broder KR, Gee J, Weintraub E, Shimabukuro T. et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the Advisory committee on immunization practices — United States, June 2021. MMWR Morb Mortal Wkly Rep. 2021;70(27):977–82. doi:10.15585/mmwr.mm7027e2.
   PubMed Web of Science ®Google Scholar
• Pillay J, Gaudet L, Wingert A, Bialy L, Mackie AS, Paterson DI, Hartling L. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following COVID-19 vaccination: living evidence syntheses and review. BMJ. 2022;378:e069445. doi:10.1136/bmj-2021-069445.
   PubMedGoogle Scholar
• Le Vu S, Bertrand M, Jabagi MJ, Botton J, Drouin J, Baricault B, Weill A, Dray-Spira R, Zureik M. Age and sex-specific risks of myocarditis and pericarditis following covid-19 messenger RNA vaccines. Nat Commun. 2022;13:3633. doi:10.1038/s41467-022-31401-5.
   PubMed Web of Science ®Google Scholar
• Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, Watkinson P, Khunti K, Harnden A, Coupland CAC. et al. Risk of myocarditis after sequential doses of COVID-19 vaccine and SARS-CoV-2 infection by age and sex. Circulation. 2022;146:743–54. doi:10.1161/CIRCULATIONAHA.122.059970.
   PubMed Web of Science ®Google Scholar
• Husby A, Gulseth HL, Hovi P, Hansen JV, Pihlström N, Gunnes N, Härkänen T, Dahl J, Karlstad Ø, Heliö T. et al. Clinical outcomes of myocarditis after SARS-CoV-2 mRNA vaccination in four Nordic countries: population based cohort study. BMJ Med. 2023;2(1):e000373. doi:10.1136/bmjmed-2022-000373.
   PubMedGoogle Scholar
• Samimisedeh P, Jafari Afshar E, Shafiabadi Hassani N, Rastad H. Cardiac MRI findings in COVID-19 vaccine-related myocarditis: a pooled analysis of 468 patients. J Magn Reson Imaging. 2022;56:971–82. doi:10.1002/jmri.28268.
   PubMed Web of Science ®Google Scholar
• Fronza M, Thavendiranathan P, Chan V, Karur GR, Udell JA, Wald RM, Hong R, Hanneman K. Myocardial injury pattern at MRI in COVID-19 vaccine–associated myocarditis. Radiology. 2022;304(3):553–62. doi:10.1148/radiol.212559.
   PubMed Web of Science ®Google Scholar
• Clinical considerations: myocarditis and pericarditis after receipt of mRNA COVID-19 vaccines among adolescents and young adults. [Internet]. United States Centers for Disease Control and Prevention; 2022 [accessed 2023 Feb 23]. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html.
   Google Scholar
• Rafaniello C, Gaio M, Zinzi A, Sullo MG, Liguori V, Ferraro M, Petronzelli F, Felicetti P, Marchione P, Marra AR. et al. Disentangling a thorny issue: myocarditis and Pericarditis post COVID-19 and following mRNA COVID-19 vaccines. Pharm (Basel). 2022;15(5):525. doi:10.3390/ph15050525.
   Google Scholar
• Fairweather D, Beetler DJ, Di Florio DN, Musigk N, Heidecker B, Cooper LT Jr. COVID-19, myocarditis and pericarditis. Circ Res. 2023;132:1302–19. doi:10.1161/CIRCRESAHA.123.321878.
   PubMed Web of Science ®Google Scholar
• Boehmer TK, Kompaniyets L, Lavery AM, Hsu J, Ko JY, Yusuf H, Romano SD, Gundlapalli AV, Oster ME, Harris AM. Association between COVID-19 and myocarditis using hospital-based administrative data — United States, March 2020–January 2020. MMWR Morb Mortal Wkly Rep. 2021 [March 2021–January 2021];70:1228–32. doi:10.15585/mmwr.mm7035e5.
   PubMed Web of Science ®Google Scholar
• Ammirati E, Lupi L, Palazzini M, Hendren NS, Grodin JL, Cannistraci CV, Schmidt M, Hekimian G, Peretto G, Bochaton T. et al. Prevalence, characteristics, and outcomes of COVID-19–associated acute myocarditis. Circulation. 2022;145(15):1123–39. doi:10.1161/CIRCULATIONAHA.121.056817.
   PubMed Web of Science ®Google Scholar
• Barmada A, Klein J, Ramaswamy A, Brodsky NN, Jaycox JR, Sheikha H, Jones KM, Habet V, Campbell M, Sumida TS. et al. Cytokinopathy with aberrant cytotoxic lymphocytes and profibrotic myeloid response in SARS-CoV-2 mRNA vaccine–associated myocarditis. Sci Immunol. 2023;8(83):eadh3455. doi:10.1126/sciimmunol.adh3455.
   PubMed Web of Science ®Google Scholar
• Moghimi SM. Allergic reactions and anaphylaxis to LNP-Based COVID-19 vaccines. Mol Ther. 2021;29:898–900. doi:10.1016/j.ymthe.2021.01.030.
   PubMed Web of Science ®Google Scholar
• Shimabukuro T, Nair N. Allergic reactions including anaphylaxis after receipt of the first dose of pfizer-BioNTech COVID-19 vaccine. JAMA. 2021;325:780–1. doi:10.1001/jama.2021.0600.
   PubMed Web of Science ®Google Scholar
• Shimabukuro TT, Cole M, Su JR. Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US—December 14, 2020-January 18, 2021. JAMA. 2021;325(11):1101–2. doi:10.1001/jama.2021.1967.
   PubMed Web of Science ®Google Scholar
• Maoz-Segal R, Shavit R, Kidon MI, Offengenden I, Machnes-Maayan D, Lifshitz-Tunitsky Y, Niznik S, Agmon-Levin N. Late hypersensitivity reactions to the BNT162b2 SARS-CoV-2 vaccine are linked to delayed skin sensitization and prior exposure to hyaluronic acid. Life (Basel). 2022;12:2021. doi:10.3390/life12122021.
   PubMed Web of Science ®Google Scholar
• Wong KK, Heilig CM, Hause A, Myers TR, Olson CK, Gee J, Marquez P, Strid P, Shay DK. Menstrual irregularities and vaginal bleeding after COVID-19 vaccination reported to v-safe active surveillance, USA in December, 2020–January, 2022: an observational cohort study. Lancet Digit Health. 2022;4(9):667–75. doi:10.1016/S2589-7500(22)00125-X.
   PubMedGoogle Scholar
• COVID-19 vaccines safety update 10 November 2022. [Internet]. European Medicines Agency; 2022 [accessed 2023 Feb 23]. https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-10-november-2022_en.pdf.
   Google Scholar
• European Medicines Agency. Signal assessment report on heavy menstrual bleeding with tozinameran/comirnaty (COVID-19 mRNA vaccine). 2022.
   Google Scholar
• Edelman A, Boniface ER, Male V, Cameron ST, Benhar E, Han L, Matteson KA, Van Lamsweerde A, Pearson JT, Darney BG. Association between menstrual cycle length and COVID-19 vaccination: global, retrospective cohort study of prospectively collected data. BMJ Med. 2022;1(1):e000297. doi:10.1136/bmjmed-2022-000297.
   PubMedGoogle Scholar
• Kim MS, Jung SY, Ahn JG, Park SJ, Shoenfeld Y, Kronbichler A, Koyanagi A, Dragioti E, Tizaoui K, Hong SH. et al. Comparative safety of mRNA COVID-19 vaccines to influenza vaccines: A pharmacovigilance analysis using WHO international database. J Med Virol. 2022;94:1085–95. doi:10.1002/jmv.27424.
   PubMed Web of Science ®Google Scholar
• Toepfner N, von Meissner WCG, Strumann C, Drinka D, Stuppe D, Jorczyk M, Moor J, Puschel J, Liss M, von Poblotzki E. et al. Comparative safety of the BNT162b2 messenger RNA COVID-19 vaccine vs other approved vaccines in children younger than 5 years. JAMA Netw Open. 2022;5:e2237140. doi:10.1001/jamanetworkopen.2022.37140.
   PubMed Web of Science ®Google Scholar
• Mangat HS, Rippon B, Reddy NT, Syed AA, Maruthanal JM, Luedtke S, Puthumana JJ, Srivatsa A, Bosman A, Kostkova P. et al. Reported rates of all-cause serious adverse events following immunization with BNT-162b in 5–17-year-old children in the United States. PLoS One. 2023;18(2):e0281993. doi:10.1371/journal.pone.0281993.
   PubMed Web of Science ®Google Scholar
• Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, Watkinson P, Khunti K, Harnden A, Coupland CAC. et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med. 2022;28:410–22. doi:10.1038/s41591-021-01630-0.
   PubMed Web of Science ®Google Scholar
• COVID-19 vaccines safety update: 14 July 2021. [Internet]. European Medicines Agency; 2022 [accessed 2023 Feb 23]. https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-comirnaty-14-july-2021_en.pdf.
   Google Scholar
• Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis. 2022;22:1293–302. doi:10.1016/S1473-3099(22)00320-6.
   PubMed Web of Science ®Google Scholar
• The Japan News. Japan OK’s pfizer vaccine for XBB.1.5 omicron variant. 2023.
   Google Scholar
• Recommendation for the 2023-2024 formula of COVID-19 vaccines in the U.S. [Internet]. U.S. Food and Drug Administration; 2023 [accessed 2023 12 Aug 2023]. https://www.fda.gov/media/169591/download.
   Google Scholar
• Pfizer and BioNTech dose first participants in the U.S. as part of global COVID-19 mRNA vaccine development program. [Internet]. Pfizer; 2020 [accessed 2023 Mar 3]. https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_biontech_dose_first_participants_in_the_u_s_as_part_of_global_covid_19_mrna_vaccine_development_program.
   Google Scholar